TY - JOUR
T1 - Radiofrequency thermal ablation of breast cancer local recurrence
T2 - A phase II clinical trial
AU - Garbay, Jean Rémi
AU - Mathieu, Marie Christine
AU - Lamuraglia, Michele
AU - Lassau, Nathalie
AU - Balleyguier, Corrine
AU - Rouzier, Roman
N1 - Funding Information:
The authors thank Michel Marty and Agnes Lap-lanche for their help in designing the trial and acknowledge support by grants from the Institut Gustave Roussy and Fondation de l’Avenir.
PY - 2008/11/1
Y1 - 2008/11/1
N2 - Background: The role of radiofrequency (RF) ablation to treat local recurrence of breast cancer is unknown. Methods: We conducted a two-stage phase II clinical trial. Eligible patients had a histologically confirmed noninflammatory and ≤3 cm ipsilateral breast tumor recurrence. The tumor site was identified by intraoperative sonography. A LeVeen needle electrode (RadioTherapeutics Corp, Mountain View, Calif) was inserted into a single site within the tumor and radiofrequency ablation was performed using a RF-2000 generator (RadioTherapeutics Corp). After completion of radiofrequency, a mastectomy was performed. Conventional staining and nicotinamide adenine dinucleotide-diaphorase (NADH-diaphorase) cell viability staining were performed. Results: During the first stage, procedures were uneventful. Conventional, cytokeratin, and NADH-diaphorase staining identified persistent viable tumor cells in the RF-ablated region in three patients. This phase II trial was stopped after completion of the first stage because of insufficient efficacy. Conclusion: We demonstrate in this study that RF ablation is a potential technique to destroy local recurrence of breast tumors but the technique we tested in this phase II clinical trial had insufficient efficacy to recommend its use in routine.
AB - Background: The role of radiofrequency (RF) ablation to treat local recurrence of breast cancer is unknown. Methods: We conducted a two-stage phase II clinical trial. Eligible patients had a histologically confirmed noninflammatory and ≤3 cm ipsilateral breast tumor recurrence. The tumor site was identified by intraoperative sonography. A LeVeen needle electrode (RadioTherapeutics Corp, Mountain View, Calif) was inserted into a single site within the tumor and radiofrequency ablation was performed using a RF-2000 generator (RadioTherapeutics Corp). After completion of radiofrequency, a mastectomy was performed. Conventional staining and nicotinamide adenine dinucleotide-diaphorase (NADH-diaphorase) cell viability staining were performed. Results: During the first stage, procedures were uneventful. Conventional, cytokeratin, and NADH-diaphorase staining identified persistent viable tumor cells in the RF-ablated region in three patients. This phase II trial was stopped after completion of the first stage because of insufficient efficacy. Conclusion: We demonstrate in this study that RF ablation is a potential technique to destroy local recurrence of breast tumors but the technique we tested in this phase II clinical trial had insufficient efficacy to recommend its use in routine.
KW - Breast cancer
KW - Breast conservation
KW - Local recurrence
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=55149094754&partnerID=8YFLogxK
U2 - 10.1245/s10434-008-0026-8
DO - 10.1245/s10434-008-0026-8
M3 - Article
C2 - 18709415
AN - SCOPUS:55149094754
SN - 1068-9265
VL - 15
SP - 3222
EP - 3226
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 11
ER -